100 Tice Blvd.
Woodcliff Lake, NJ 07677

Eisai News

EISAI: Eisai And Merck Provide Update on Supplemental New Drug Application (sNDA) for Lenvatinib in First-Line Unresectable Hepatocellular Carcinoma

Eisai Inc. and Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has extended the action date for the supplemental New Drug Application (sNDA) for lenvatinib for the potential first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). Read More »

New FYCOMPA data presented at ECE

Eisai Inc. last week announced that new data on FYCOMPA (perampanel) CIII presented at the 12th European Congress on Epileptology (ECE) has shown that adjunctive use of the medication for up to two-and-a-half years has proven to deliver persistent seizure control in patients suffering from primary generalized tonic clonic (PGTC) seizures who have been poorly controlled. Read More »